Want to see AU:SNT full AI Analyst Report?

Syntara Limited (SNT) Price & Analysis

17 Followers

SNT Stock Chart & Stats

AU$0.03

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.03

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.04

Previous CloseN/A

Volume167.43K

Average Volume (3M)1.97M

Market Cap

AU$36.34M

Enterprise ValueAU$21.58M

Total Cash (Recent Filing)AU$13.56M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.70

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,964,519,300

10 Day Avg. Volume1,947,114

30 Day Avg. Volume1,968,440

Financial Highlights & Ratios

PEG Ratio-0.47

Price to Book (P/B)1.91

Price to Sales (P/S)4.48

P/FCF Ratio-3.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageThe absence of debt and sizeable equity base reduce solvency and refinancing pressure compared with earlier periods of higher leverage. This gives Syntara greater balance-sheet flexibility to support clinical development and absorb operating volatility over the next several quarters.

Specialised Drug PlatformA focused amine oxidase platform gives Syntara a defined scientific foundation across fibrosis and oncology rather than an undifferentiated drug pipeline. If development advances, platform reuse across indications could support broader clinical opportunities from shared expertise.

Historical Gross ProfitabilityThe historical gross margin indicates that Syntara’s underlying offerings generated positive gross economics when revenue was present. Although current revenue is absent, this prior evidence provides some support that eventual commercialisation could produce value before operating costs are considered.

Bears Say

No Recent RevenueThe absence of reported revenue means Syntara currently lacks an established commercial earnings stream to fund operations or validate market adoption. This leaves future financial performance dependent on successful development and eventual commercialisation rather than recurring business activity.

Persistent Net LossesContinuing and worsening net losses show that the business is not yet converting its development activity into sustainable profitability. Persistent operating deficits can erode the equity base over time and increase the importance of successful pipeline execution for long-term financial viability.

Ongoing Cash BurnNegative operating and free cash flow demonstrate that current activities consume cash rather than self-fund growth. Even with low debt, sustained burn can reduce liquidity and require additional funding, making development continuity increasingly dependent on capital access.

Syntara Limited News

Syntara advances Parkinson’s, MDS and scar programs on solid R&D footing

Syntara Limited ( ($AU:SNT) ) has shared an announcement. Syntara Limited reported a strong September quarter marked by...

2d ago

Syntara moves AGM fully online as it boosts digital engagement with investors

The latest announcement is out from Syntara Limited ( ($AU:SNT) ). Syntara Limited has scheduled its annual general...

12d ago

Syntara Flags Risks Around Drug and Device Pipeline

An update from Syntara Limited ( ($AU:SNT) ) is now available. Syntara Limited operates in the pharmaceutical and...

19d ago

Syntara Issues New Unquoted Performance Rights Under Employee Incentive Plan

Syntara Limited ( ($AU:SNT) ) has issued an update. Syntara Limited has notified the market of the issue...

27d ago

Syntara Issues 34.9 Million Unquoted Performance Rights Under Incentive Scheme

Syntara Limited ( ($AU:SNT) ) has shared an update. Syntara Limited, traded on the ASX under ticker SNT,...

27d ago

Syntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy

Syntara Limited ( ($AU:SNT) ) has issued an announcement. Syntara Limited is a clinical-stage biopharmaceutical company developing topical...

1M ago

Syntara boosts R&D funding with A$4.7m tax incentive

The latest announcement is out from Syntara Limited ( ($AU:SNT) ). Syntara Limited has secured an A$4.7 million...

1M ago

Syntara Seeks ASX Quotation for 1.5 Million New Shares

Syntara Limited ( ($AU:SNT) ) has issued an announcement. Syntara Limited has lodged an application with the ASX...

2M ago

Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline

Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited, an ASX-listed clinical-stage biotechnology company based in...

2M ago

Syntara Loss Widens as Revenue Falls and Asset Base Shrinks

Syntara Limited ( ($AU:SNT) ) has shared an announcement. For the 2026 financial year, Syntara reported a 7.9%...

2M ago

SNT FAQ

What was Pharmaxis Ltd’s price range in the past 12 months?

Pharmaxis Ltd lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.

What is Pharmaxis Ltd’s market cap?

Pharmaxis Ltd’s market cap is AU$36.34M.

When is Pharmaxis Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pharmaxis Ltd’s earnings last quarter?

Currently, no data Available

Is Pharmaxis Ltd overvalued?

According to Wall Street analysts Pharmaxis Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Pharmaxis Ltd pay dividends?

Pharmaxis Ltd does not currently pay dividends.

What is Pharmaxis Ltd’s EPS estimate?

Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaxis Ltd have?

Pharmaxis Ltd has 1,964,519,300 shares outstanding.

What happened to Pharmaxis Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharmaxis Ltd?

Currently, no hedge funds are holding shares in AU:SNT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Syntara Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-67.08%

Trailing 12-Months

Asset Growth

-10.75%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharmaxis Ltd

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.